• Nebi Serkan Demirci, Eyyüp Çavdar, Gokmen Umut Erdem, Engin Hatipoglu, Emir Celik, Sevilay Sezer, Ahmet Yolcu, Mutlu Dogan, and Erdogan Selcuk Seber.
• Department of Medical Oncology, Faculty of Medicine, Istanbul University-Cerrahpasa Cerrahpasa, Turkey.
• Medicine (Baltimore). 2023 Jun 23; 102 (25): e34014e34014.

AbstractIn the present study, we aimed to assess the association between the serum survivin level and overall survival and treatment response rates in metastatic pancreatic cancer (MPC). Serum samples were prospectively collected from 41 patients with newly diagnosed MPC patients and 41 healthy individuals (control group) to assess the survivin levels. The median survivin level was 136.2 ng/mL in patients with MPC and 52 ng/mL in healthy individuals (P = .028). Patients were divided into low- and high-survivin groups according to the baseline median survivin level. Patients with a high serum survivin level compared with a low serum survivin level had shorter median progression-free survival (2.39 vs 7.06 months; P = .008, respectively) and overall survival (3.74 vs 9.52 months; P = .026, respectively). Patients with higher serum survivin levels had significantly worse response rates (P = .007). The baseline high level of serum survivin in patients with MPC may be associated with treatment resistance and poor prognosis. A confirmation will be needed for these results in future large multicenter prospective studies.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

20 keywords...

hide…